期刊
BRITISH JOURNAL OF CANCER
卷 115, 期 7, 页码 776-783出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/bjc.2016.249
关键词
BRCA2 mutation; breast cancer; oestrogen receptor; prognostic factors; treatment; survival
类别
资金
- Icelandic Cancer Society
- Icelandic Centre for Research [14193-051]
- Icelandic breast cancer research support group Gongum saman
Background: The impact of an inherited BRCA2 mutation on the prognosis of women with breast cancer has not been well documented. We studied the effects of oestrogen receptor (ER) status, other prognostic factors and treatments on survival in a large cohort of BRCA2 mutation carriers. Methods: We identified 285 breast cancer patients with a 999del5 BRCA2 mutation and matched them with 570 non-carrier patients. Clinical information was abstracted from patient charts and pathology records and supplemented by evaluation of tumour grade and ER status using archived tissue specimens. Univariate and multivariate hazard ratios (HR) were estimated for breast cancer-specific survival using Cox regression. The effects of various therapies were studied in patients treated from 1980 to 2012. Results: Among mutation carriers, positive ER status was associated with higher risk of death than negative ER status (HR = 1.94; 95% CI = 1.22-3.07, P = 0.005). The reverse association was seen for non-carriers (HR = 0.71; 95% CI: 0.51-0.97; P = 0.03). Conclusions: Among BRCA2 carriers, ER-positive status is an adverse prognostic factor. BRCA2 carrier status should be known at the time when treatment decisions are made.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据